Harbour BioMed Appoints Dr. Jenny Xie as Chief Scientific Officer, Immunology and Head of Global External Innovation

Dr. Xie will lead the company's global external innovation strategy in immunology and oversee activities at the Harbour BioMed-AstraZeneca Innovation Lab in Beijing.

Mar. 19, 2026 at 7:25am

Got story updates? Submit your updates here. ›

Harbour BioMed, a global biopharmaceutical company, has announced the appointment of Dr. Jenny Xie as Chief Scientific Officer, Immunology and Head of Global External Innovation. In this role, Dr. Xie will lead the company's global external innovation strategy in immunology, manage ongoing strategic collaborations, and identify and pursue new partnership opportunities. She will also oversee activities at the Harbour BioMed-AstraZeneca Innovation Lab in Beijing.

Why it matters

The appointment of Dr. Xie, an experienced leader in drug discovery and development in immunology, is expected to significantly advance Harbour BioMed's immunology research and global collaboration efforts as the company works to strengthen its R&D capabilities and drive innovation across its pipeline.

The details

Dr. Xie will be based in Shanghai and report directly to Dr. Jingsong Wang, Founder, Chairman and Chief Executive Officer of Harbour BioMed. Prior to joining Harbour BioMed, she served as Executive Director and Head of Discovery Immunology at Bristol Myers Squibb, where she led research efforts in autoimmune diseases and contributed to the discovery, evaluation, and clinical translation of novel therapeutic approaches. She has over 25 years of experience in the biopharmaceutical industry, including scientific leadership roles at Merck.

  • Dr. Xie's appointment was announced on March 19, 2026.

The players

Harbour BioMed

A global biopharmaceutical company focused on the discovery and development of novel antibody therapeutics in immunology and oncology.

Dr. Jenny Xie

The newly appointed Chief Scientific Officer, Immunology and Head of Global External Innovation at Harbour BioMed.

Dr. Jingsong Wang

The Founder, Chairman and Chief Executive Officer of Harbour BioMed.

Bristol Myers Squibb

A pharmaceutical company where Dr. Xie previously served as Executive Director and Head of Discovery Immunology.

Merck

A pharmaceutical company where Dr. Xie held scientific leadership roles prior to joining Harbour BioMed.

Got photos? Submit your photos here. ›

What they’re saying

“We are very pleased to welcome Dr. Jenny Xie to our executive team. Her extensive experience in drug discovery and development in immunology will be invaluable as we work to strengthen our R&D capabilities and drive innovation across our pipeline. I am confident her leadership will significantly advance our immunology research and global collaboration efforts.”

— Dr. Jingsong Wang, Founder, Chairman, and CEO of Harbour BioMed

“I am truly excited to join an incredible company like Harbour BioMed and look forward to working with everyone toward our shared goal of transforming patients' lives through innovation, speed, and global collaboration.”

— Dr. Jenny Xie, Chief Scientific Officer, Immunology and Head of Global External Innovation of Harbour BioMed

The takeaway

The appointment of Dr. Jenny Xie, an experienced leader in immunology research and drug development, is expected to strengthen Harbour BioMed's R&D capabilities and drive innovation in its pipeline of novel antibody therapeutics, further positioning the company as a global leader in the biopharmaceutical industry.